glp 1 agonist comparison Comparing Ozempic, Wegovy and Other GLP-1 Drugs The role of glucagon-like peptide-1

Jos Manuel Carrascosa has participated as PI/SI and/or guest presenter and/or advisor for Almirall, Janssen, Abbvie, UCB, Boehringer-Ingelheim, Lilly, Novartis, Amgen, BMS, and Sandoz

Reduced levels of the mitochondrial autophagy-associated protein Parkin in the substantia nigra may contribute to the development of Parkinsons disease (PD) in db/db mice and high-fat diet-induced diabetic mice

What foods enhance GLP-1 activity

Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available

DA Wallachs Zero Toll Medicine was an ambitious read into how AI and automation could make healthcare significantly cheaper.

Rosenstock, J., Frias, J., Jastreboff, A